Table 1 Characteristics of randomised controlled trials included in the meta-analysis
From: Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
Source | No. of participants (Intervention) | Duration treatment, wk | Age, Mean | Male % | Time since diagnosis, yr | FVC, %, mean | Risk of biasa |
|---|---|---|---|---|---|---|---|
Noble et al. 2011 [4] (Capacity 06) | 171 (Pirfenidone 2403 mg/day) | 72 | 67 | 72 | ≤1 yr: 59% | 74 | Low |
173 (Placebo) | |||||||
Noble et al. 2011 [4] (Capacity 04) | 174 (Pirfenidone 2403 mg/day) | 72 | 66 | 71 | ≤1 yr: 48% | 75 | Low |
174 (Placebo) | |||||||
Taniguchi et al. 2010 [5] | 108 (Pirfenidone 1800 mg/day) | 52 | 65 | 78 | <1 yr: 37% | 78 | Unclear |
104 (Placebo) | |||||||
Azuma et al. 2005 [6] | 73 (Pirfenidone 1800 mg/day) | 39 | 64 | 90 | <1 yr: 22% | 80 | Unclear |
36 (Placebo) | |||||||
King et al. 2014 [7] (Ascend) | 278 (Pirfenidone 2403 mg/day) | 52 | 68 | 78 | 1.7 | 68 | Low |
277 (Placebo) | |||||||
Richeldi et al. 2011 [25] | 85 (Nintedanib 300 mg/day) | 52 | 65 | 75 | 1.2 | 80 | Low |
85 (Placebo) | |||||||
Richeldi et al. 2014 [8] (INPULSIS-1) | 309 (Nintedanib 300 mg/day) | 52 | 67 | 81 | 1.7 | 80 | Low |
204 (Placebo) | |||||||
Richeldi et al. 2014 [8] (INPULSIS-2) | 329 (Nintedanib 300 mg/day) | 52 | 67 | 78 | 1.6 | 79 | Low |
219 (Placebo) | |||||||
Homma et al. 2012 [24], | 38 (Inhaled NAC) | 48 | 68 | 76 | 3 | 89 | Unclear |
38 (Placebo) | |||||||
Raghu et al. 2012 [22], (PANTHER) | 77 (NAC triple therapy) | 32 | 68 | 75 | 1.1 | 71 | Low |
78 (Placebo) | |||||||
IPFCRN, 2014 [23] (PANTHER) | 133 (NAC) | 60 | 68 | 78 | 1.1 | 73 | Low |
131 (Placebo) |